Drugs / AGN-193408
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04499248 | Nov 2020 → Apr 2029 expected | ocular hypertension, open-angle glaucoma | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-193408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04499248 ↗ |